NASDAQ:ADAG - Adagene Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside: 137.74 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.46
▲ +0.03 (0.22%)
1 month | 3 months | 12 months
Get New Adagene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADAG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADAG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.00
▲ +137.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adagene in the last 3 months. The average price target is $32.00, with a high forecast of $34.00 and a low forecast of $29.00. The average price target represents a 137.74% upside from the last price of $13.46.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Adagene.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021Morgan StanleyInitiated CoverageOverweight$34.00Low
i
3/15/2021Jefferies Financial GroupInitiated CoverageBuy$33.00Low
i
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$33.00High
i
3/8/2021Morgan StanleyInitiated CoverageOverweight$34.00High
i
3/5/2021The Goldman Sachs GroupInitiated CoverageBuy$29.00High
i
(Data available from 4/14/2016 forward)
Adagene logo
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.
Read More

Today's Range

Now: $13.46
$13.20
$13.89

50 Day Range

MA: $20.34
$13.43
$26.24

52 Week Range

Now: $13.46
$13.05
$31.83

Volume

18,589 shs

Average Volume

95,853 shs

Market Capitalization

$582.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Adagene?

The following Wall Street analysts have issued reports on Adagene in the last year: Jefferies Financial Group Inc., Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ADAG.

What is the current price target for Adagene?

3 Wall Street analysts have set twelve-month price targets for Adagene in the last year. Their average twelve-month price target is $32.00, suggesting a possible upside of 137.7%. Morgan Stanley has the highest price target set, predicting ADAG will reach $34.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $29.00 for Adagene in the next year.
View the latest price targets for ADAG.

What is the current consensus analyst rating for Adagene?

Adagene currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADAG will outperform the market and that investors should add to their positions of Adagene.
View the latest ratings for ADAG.

What other companies compete with Adagene?

How do I contact Adagene's investor relations team?

The company's listed phone number is 86 512 8777 3632. The official website for Adagene is www.adagene.com.